Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells

BACKGROUND: Patients affected by aggressive B-cell malignancies who are resistant to primary or salvage chemoimmunotherapy have an extremely poor prognosis and limited therapeutic options. Promising therapeutic success has been achieved with the infusion of CD19 chimeric antigen receptor-T cells, bu...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Immunother Cancer
Κύριοι συγγραφείς: Pietà, Anna Dalla, Cappuzzello, Elisa, Palmerini, Pierangela, Ventura, Annavera, Visentin, Andrea, Astori, Giuseppe, Chieregato, Katia, Mozzo, Valentina, Perbellini, Omar, Tisi, Maria Chiara, Trentin, Livio, Visco, Carlo, Ruggeri, Marco, Sommaggio, Roberta, Rosato, Antonio
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BMJ Publishing Group 2021
Θέματα:
Clinical/Translational Cancer Immunotherapy
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8287629/
https://ncbi.nlm.nih.gov/pubmed/34272306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002475
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια